Annovis Bio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated June 13, 2024, reports on the results of Annovis Bio, Inc.'s 2024 Annual Meeting of Stockholders held virtually on June 12, 2024. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Malvern, PA.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A total of 7,278,396 shares, representing 66.10% of the common stock outstanding as of the April 18, 2024 record date, were represented at the meeting. All three proposals submitted were approved:
- Election of Directors: All five nominees (Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White) were elected to the Board of Directors for a one-year term.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2019 Equity Incentive Plan to add 1,000,000 shares to the plan's share reserve.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent auditors for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves solely as a disclosure of the voting results.
Key Facts for Investor Verification
- Verify the impact of the 1,000,000 share increase to the 2019 Equity Incentive Plan on potential future dilution.
- Confirm the composition of the newly elected Board of Directors and their tenure terms.
- Review the definitive proxy statement referenced in the filing for detailed background on the proposals.